Richter Gedeon upgraded pharma outlook while Richter Gedeon stock trades at EUR 33.80

Published on 10/13/2026 at 10:07 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

H1 revenue reached HUF 151.8 billion, up 3.00 percent year over year. Richter Gedeon stock was at EUR 33.80 during trading on October 13, 2026.

Key points in brief

Richter Gedeon upgraded its 2026 pharma Clean EBIT outlook to double-digit constant-currency growth on August 7, 2026.
First-half revenue reached HUF 151.8 billion, up 3.00 percent year over year, while constant-currency revenue grew 8.70 percent.
The stock was trading at EUR 33.80 at Lang & Schwarz on October 13, 2026 at 9:59 a.m. CEST.
Yahoo Finance lists November 10, 2026 as the next earnings date.

Richter Gedeon, HU0000123096, Illustration mit AI erstellt.

Richter Gedeon (HU0000123096) was trading at EUR 33.80 at Lang & Schwarz on October 13, 2026 at 9:59 a.m. CEST. On August 7, 2026, the company upgraded its 2026 pharma Clean EBIT outlook to double-digit constant-currency growth, according to Yahoo Finance.

First-half growth supports guidance

Revenue reached HUF 151.8 billion in the first half of 2026, an increase of 3.00 percent from the year-earlier period. Constant-currency revenue growth was 8.70 percent, while constant-currency Clean EBIT increased 21.00 percent, according to Yahoo Finance.

The operating picture is uneven. Biotech revenue grew 30.00 percent in constant currency, while general medicines remained below the companys original plan and management described a recovery toward mid-single-digit growth from 2027.

What does the guidance change mean?

The upgrade centers on profitability rather than a new revenue target. Management attributed the improvement to VRAYLAR performance, restructuring benefits and lower overhead, while the biotechnology unit moved closer to break-even expectations.

Foreign exchange remains a counter-factor. Reported net profit fell to HUF 103.5 billion in the first half of 2026, and the company said currency effects reduced the reported result despite stronger underlying profitability.

Three dated company milestones

On August 7, 2026, Richter Gedeon presented its first-half results and upgraded pharma Clean EBIT expectations. On September 29, 2026, the companys Next Step psychiatric conference drew 145 participants from 27 countries, according to Finanznachrichten. On October 12, 2026, its Richter Health City program reported HUF 158.4 million in support and 14,000 screenings, according to Richter Gedeon.

Next reporting date

Yahoo Finance lists November 10, 2026 as the next earnings date for the company, giving the market a scheduled point to test the upgraded profitability outlook.

Stock trades at EUR 33.80

Richter Gedeon was trading at EUR 33.80 at Lang & Schwarz on October 13, 2026 at 9:59 a.m. CEST. The Budapest-listed pharmaceutical group has exposure to central nervous system medicines, womens healthcare, general medicines and biotechnology.

The further course of trading is shown by the continuously updated real-time quote of Richter Gedeon stock.